Who are Cellectis S.A.'s main suppliers?

Cellectis S.A. (CLLS) key suppliers include: ALLOGENE, AstraZeneca PLC, AstraZeneca PLC, SERVIER, INSTITUT-DE-RECHERCHES-INTERNATIONALES-SERVIER-S and 3 more. View the full supplier network at chainsifter.com/chain/CLLS.

Who are Cellectis S.A.'s major customers?

Cellectis S.A. (CLLS) key customers include: Allogene Therapeutics, Inc., Iovance Biotherapeutics, Inc., Allogene Therapeutics, Inc., Autolus Therapeutics plc, Autolus Therapeutics plc and 18 more. View the full customer network at chainsifter.com/chain/CLLS.

What sector is Cellectis S.A. in?

Cellectis S.A. (CLLS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Cellectis S.A. Suppliers, Customers & Supply Chain (CLLS)

8Suppliers

23Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

Cellectis S.A. (CLLS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

33Total relationships

1Distinct source URLs

10High confidence

0.761Average confidence

2026-10-29Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Cellectis S.A. Suppliers

Ticker	Name	Confidence	Evidence
ALLOGENE	ALLOGENE	90%	We have entered into licensing or collaboration agreements with partners, such as Allogene, Servier and AstraZeneca under which our partners have or have the right to obtain exclusive development and…
AZN	AstraZeneca PLC	90%	We have entered into licensing or collaboration agreements with partners, such as Allogene, Servier and AstraZeneca under which our partners have or have the right to obtain exclusive development and…
AZN	AstraZeneca PLC	90%	Reciprocal relationship from AZN graph: Reciprocal relationship from CLLS graph: We have entered into licensing or collaboration agreements with partners, such as Allogene, Servier and AstraZeneca un…
SERVIER	SERVIER	90%	We have entered into licensing or collaboration agreements with partners, such as Allogene, Servier and AstraZeneca under which our partners have or have the right to obtain exclusive development and…
INSTITUT-DE-RECHERCHES-INTERNATIONALES-SERVIER-S	INSTITUT-DE-RECHERCHES-INTERNATIONALES-SERVIER-S	80%	Under the License, Development and Commercialization Agreement dated March 6, 2019, between us and Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, "…
LES-LABORATOIRES-SERVIER-SAS	LES-LABORATOIRES-SERVIER-SAS	80%	Under the License, Development and Commercialization Agreement dated March 6, 2019, between us and Les Laboratoires Servier SAS and Institut de Recherches Internationales Servier SAS (collectively, "…
ALLO	Allogene Therapeutics, Inc.	72%	Reciprocal relationship from ALLO graph: is equal to nine times the total amount awarded and paid to the Company. After completing the CIRM funded research project and at any time after the award per…
DTIL	Precision BioSciences, Inc.	72%	Reciprocal relationship from DTIL graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from DTIL graph: es pursuant to inspections that will be conducted after we submit an applica…

Cellectis S.A. Customers

Ticker	Name	Confidence	Evidence
ALLO	Allogene Therapeutics, Inc.	90%	Reciprocal relationship from ALLO graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from ALLO graph: the Company acquired certain assets and assumed certain liabilities from Pfi…
IOVA	Iovance Biotherapeutics, Inc.	85%	Reciprocal relationship from IOVA graph: The Company will license gene-editing technology from Cellectis S.A. to develop TIL cell therapies that have been genetically edited, including a PD-1 inactiv…
ALLO	Allogene Therapeutics, Inc.	72%	01 23,658 Gross value at end of period 53,751 18,332 72,083 Accumulated depreciation at end of period ( 31,994 ) ( 16,431 ) ( 48,425 ) Entity-wide disclosures: In 2025, approximately $ 8.3 million o …
AUTL	Autolus Therapeutics plc	72%	ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia…
AUTL	Autolus Therapeutics plc	72%	Reciprocal relationship from AUTL graph: Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw an…
BMY	Bristol-Myers Squibb Company	72%	ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia…
BMY	Bristol-Myers Squibb Company	72%	Reciprocal relationship from BMY graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from BMY graph: Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manufac…
BMYMP	Bristol-Myers Squibb Co	72%	Reciprocal relationship from BMYMP graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from BMYM…
BMYMP	Bristol-Myers Squibb Co	72%	ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia…
DTIL	Precision BioSciences, Inc.	72%	Reciprocal relationship from DTIL graph: Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw an…
DTIL	Precision BioSciences, Inc.	72%	ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia…
IOVA	Iovance Biotherapeutics, Inc.	72%	han we anticipate or may result in delays. In addition, if supply from one approved manufacturer or supplier, including our own in-house manufacturing facilities, is interrupted, there could be a sig…
LYEL	Lyell Immunopharma, Inc.	72%	ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia…
LYEL	Lyell Immunopharma, Inc.	72%	Reciprocal relationship from LYEL graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from LYEL graph: Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manuf…
NTLA	Intellia Therapeutics, Inc.	72%	ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia…
NTLA	Intellia Therapeutics, Inc.	72%	Reciprocal relationship from NTLA graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from NTLA graph: Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manuf…
PGEN	Precigen, Inc.	72%	Reciprocal relationship from PGEN graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from PGEN graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from PGEN g…
TKPHF	Takeda Pharmaceutical Company Limited	72%	ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia…
TKPHF	Takeda Pharmaceutical Company Limited	72%	Reciprocal relationship from TKPHF graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from TKPH…
TMO	Thermo Fisher Scientific Inc.	72%	ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and starting material for clinical supply, with the potential to supply such materia…
TMO	Thermo Fisher Scientific Inc.	72%	Reciprocal relationship from TMO graph: Reciprocal relationship from CLLS graph: ately 14,000 sq. ft. in-house manufacturing facility, which is dedicated to the production of certain critical raw and…
AZN	AstraZeneca PLC	62%	Reciprocal relationship from AZN graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from CLLS graph: Reciprocal relationship from AZN grap…
FACTOR-BIOSCIENCES-INC	FACTOR-BIOSCIENCES-INC	62%	han we anticipate or may result in delays. In addition, if supply from one approved manufacturer or supplier, including our own in-house manufacturing facilities, is interrupted, there could be a sig…

Cellectis S.A. Debt Obligations

Instrument	Description	Confidence	Evidence
CLLS-DEBT	Debt stack $32.2M	90%	Market cache reports total debt of $32.2M.

Cellectis S.A. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Cellectis S.A..

Cellectis S.A. Ownership

Holder	Name	Confidence	Evidence
CLLS-OWNER-B-GROUP-INC	B Group, Inc.	90%	13F overlay lists B Group, Inc. as top holder; 33 tracked holders.

Cellectis S.A. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CTMX	CytomX Therapeutics, Inc.	100.00	2
CPMV	Mosaic ImmunoEngineering, Inc.	100.00	2
EDIT	Editas Medicine, Inc.	100.00	2
ALLO	Allogene Therapeutics, Inc.	100.00	1	['customer', 'supplier']
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
BTAI	BioXcel Therapeutics, Inc.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
AUTL	Autolus Therapeutics plc	100.00	1	['customer']
CRBU	Caribou Biosciences, Inc.	100.00	2
REGN	Regeneron Pharmaceuticals, Inc.	100.00	2
EMMA	Emmaus Life Sciences, Inc.	100.00	2
CLYM	Climb Bio, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
BEAM	Beam Therapeutics Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
DTIL	Precision BioSciences, Inc.	100.00	1	['customer', 'supplier']
AZN	AstraZeneca PLC	100.00	1	['customer', 'supplier']
ARTV	Artiva Biotherapeutics, Inc.	100.00	2

Cellectis S.A. Supply Chain